Francis P. Worden

University of Michigan — United States

Medicine · Health Sciences

64h-index21.7kcitations547works4.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Head and Neck Cancer Studies(261), Lung Cancer Treatments and Mutations(81), Thyroid Cancer Diagnosis and Treatment(71), Salivary Gland Tumors Diagnosis and Treatment(67), Head and Neck Surgical Oncology(60)

Publications546 total

Supplementary Table 3 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial
2026Open Access
Supplementary Table 1 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial
2026Open Access
Supplementary Figure 2 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial
2026Open Access
Supplementary Table 2 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial
2026Open Access
Supplementary Figure 5 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial
2026Open Access
Supplementary Table 4 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial
2026Open Access
Data from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial
2026Open Access
Supplementary Table 6 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial
2026Open Access
Supplementary Data 1 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial
2026Open Access
Supplementary Figure 1 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial
2026Open Access
Supplementary Figure 4 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial
2026Open Access
Supplementary Table 5 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial
2026Open Access
Supplementary Figure 3 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial
2026Open Access
Prevalence and clinical characteristics of Lynch syndrome-associated adrenocortical carcinoma
Endocrine Related Cancer·2026
Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios Predict Improved Survival and Response to Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Larynx
Head & Neck·2025Open Access
FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial
Clinical Cancer Research·2025Open Access
Supplementary Table 5 from Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer
2025Open Access
Supplementary Table 4 from Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer
2025Open Access
Supplementary Table S3 from A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck
2025Open Access
Supplementary Table S1 from A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck
2025Open Access
page 1 of 28Next →

Frequent Co-authors

Avraham Eisbruch(18), Carol R. Bradford(17), Mark E. Prince(15), Gregory T. Wolf(15), Douglas B. Chepeha(15), Thomas E. Carey(11), Nabil F. Saba(10), Susan G. Urba(9), Theodoros N. Teknos(9), Robert I. Haddad(8), Jeffrey S. Moyer(8), Everett E. Vokes(7), Kitrina G. Cordell(7), Jonathan B. McHugh(7), George R. Blumenschein(6), Jérôme Fayette(6), A. Dimitrios Colevas(6), Lisa Licitra(6), Kevin J. Harrington(6), Maura L. Gillison(6)